Trial · NCT00965731
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | 2 | participants | ||
| Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | 3 | participants | ||
| PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D1 Crizotinib (N=7, 19) | 581.9 | Geometric Coefficient of Variation 49 | ng*hr/mL |
| PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D1 Crizotinib (N=7, 19) | 400.3 | Geometric Coefficient of Variation 40 | ng*hr/mL |
| PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D15 Crizotinib (N=5, 14) | 2274 | Geometric Coefficient of Variation 43 | ng*hr/mL |
| PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D15 Crizotinib (N=5, 14) | 1720 | Geometric Coefficient of Variation 40 | ng*hr/mL |
| PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D1 Crizotinib (N=7, 19) | 86.75 | Geometric Coefficient of Variation 37 | ng/mL |
| PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D1 Crizotinib (N=7, 19) | 65.31 | Geometric Coefficient of Variation 50 | ng/mL |
| PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D15 Crizotinib (N=5, 14) | 251.0 | Geometric Coefficient of Variation 46 | ng/mL |
| PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D15 Crizotinib (N=5, 14) | 185.9 | Geometric Coefficient of Variation 40 | ng/mL |
| PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | 88.02 | Geometric Coefficient of Variation 43 | L/hr | |
| PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | 87.20 | Geometric Coefficient of Variation 40 | L/hr | |
| PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D1 PF-06260182 (N=7, 19) | 16.48 | Geometric Coefficient of Variation 58 | ng*hr/mL |
| PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D1 PF-06260182 (N=7, 19) | 14.03 | Geometric Coefficient of Variation 72 | ng*hr/mL |
| PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D15 PF-06260182 (N=5, 14) | 60.36 | Geometric Coefficient of Variation 63 | ng*hr/mL |
| PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D15 PF-06260182 (N=5, 14) | 57.77 | Geometric Coefficient of Variation 66 | ng*hr/mL |
| PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D1 PF-06260182 (N=7, 19) | 2.625 | Geometric Coefficient of Variation 49 | ng/mL |
| PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D1 PF-06260182 (N=7, 19) | 2.087 | Geometric Coefficient of Variation 63 | ng/mL |
| PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (200 mg) and Erlotinib (100 mg) | C1D15 PF-06260182 (N=5, 14) | 7.093 | Geometric Coefficient of Variation 54 | ng/mL |
| PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1) | PF-02341066 (150 mg) and Erlotinib (100 mg) | C1D15 PF-06260182 (N=5, 14) | 6.508 | Geometric Coefficient of Variation 63 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00965731/results